Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: Randomized, double-blind, cross-over trial

European Heart Journal

Volumn 36, Issue 10, 2015, Pages 615-622

  Ulrich, Silvia ^a   Keusch, Stephan ^a   Hildenbrand, Florian F ^a   Lo Cascio, Christian ^a   Huber, Lars C ^a   Tanner, Felix C ^b   Speich, Rudolf ^a   Bloch, Konrad E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Hypertension " Pulmonary " Pulmonary heart disease " Sleep " Hypoxia

Indexed keywords

ACETAZOLAMIDE; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; OXYGEN;

ADULT; AGED; ANOXIA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EXERCISE TOLERANCE; FEMALE; HUMAN; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SLEEP APNEA SYNDROMES; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ACETAZOLAMIDE; ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIHYPERTENSIVE AGENTS; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; DIURETICS; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OXYGEN; SLEEP APNEA SYNDROMES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924409283     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht540     Document Type: Article

References (46)

1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009;34:1219-1263
2. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S78-S84
3. Millman RP, Kramer NR. Sleep disorders and outpatient treatment of patients with pulmonary disease. Curr Opin Pulm Med 1996;2:507-512
4. Marshall C, Marshall B. Site and sensitivity for stimulation of hypoxic pulmonary vasoconstriction. J Appl Physiol 1983;55:711-716
5. Ulrich S, Fischler M, Speich R, Bloch KE. Sleep-related breathing disorders in patients with pulmonary hypertension. Chest 2008;133:1375-1380
6. Hildenbrand FF, Bloch KE, Speich R, Ulrich S. Daytime measurements underestimate nocturnal oxygen desaturations in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Respiration 2012;84:477-484
7. Schulz R, Baseler G, Ghofrani HA, Grimminger F, Olschewski H, SeegerW. Nocturnal periodic breathing in primary pulmonary hypertension. Eur Respir J 2002;19: 658-663
8. Sands SA, Edwards BA, Kee K, Turton A, Skuza EM, Roebuck T, O"Driscoll DM, Hamilton GS, Naughton MT, Berger PJ. Loop gain as a means to predict a positive airway pressure suppression of Cheyne-Stokes respiration in patients with heart failure. Am J Respir Crit Care Med 2011;184:1067-1075
9. Javaheri S. Acetazolamide improves central sleep apnea in heart failure: a doubleblind, prospective study. Am J Respir Crit Care Med 2006;173:234-237
10. Sasayama S, Izumi T, Seino Y, Ueshima K, Asanoi H. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and Cheyne-Stokes respiration. Circ J 2006;70:1-7
11. ATS statement: guidelines for the six-minute walk test.AmJ Respir Crit CareMed2002; 166:111-117
12. Keller SD, Bayliss MS, Ware JE Jr, Hsu MA, Damiano AM, Goss TF. Comparison of responses to SF-36 Health Survey questions with one-week and four-week recall periods. Health Serv Res 1997;32:367-384
13. Cenedese E, Speich R, Dorschner L, Ulrich S, Maggiorini M, Jenni R, Fischler M. Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006;28:808-815
14. Bloch KE, Schoch OD, Zhang JN, RussiEW. German version of the Epworth sleepiness scale. Respiration 1999;66:440-447
15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography"s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463
16. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685-713; quiz 86-8
17. Thurnheer R, Xie X, Bloch KE. Accuracy of nasal cannula pressure recordings for assessment of ventilation during sleep.Am J Respir Crit Care Med 2001;164:1914-1919
18. Bloch KE. Polysomnography: a systematic review. TechnolHealth Care 1997;5:285-305
19. Dinges DF, Pack F, Williams K, Gillen KA, Powell JW, Ott GE, Aptowicz C, Pack AI. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4-5 h per night. Sleep 1997;20: 267-277
20. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
21. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ. Interpretation of treatment changes in six-minute walk distance in patients with COPD. Eur Respir J 2008;32:637-643
22. Pepke-Zaba J, Gilbert C, Collings L, Brown MC. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008;133: 183-189
23. Little RJ, D"Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012;367:1355-1360
24. Robin ED, Whaley RD, Crump CH, Travis DM. Alveolar gas tensions, pulmonary ventilation and blood pH during physiologic sleep in normal subjects. J Clin Invest 1958;37:981-989
25. Gonzales JU, Scheuermann BW. Effect of acetazolamide on respiratory muscle fatigue in humans. Respir Physiol Neurobiol 2013;185:386-392
26. Minai OA, Pandya CM, Golish JA, Avecillas JF, McCarthy K, Marlow S, Arroliga AC. Predictors of nocturnal oxygen desaturation in pulmonary arterial hypertension. Chest 2007;131:109-117
27. Jilwan FN, Escourrou P, Garcia G, Jais X, Humbert M, Roisman G. High occurrence of hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension and mechanisms. Chest 2012. .
28. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-Analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
29. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-2100
30. Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB. Addition of sildenafil to long-Term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-530
31. Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galie N. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011;30: 632-643
32. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004;24:1007-1010
33. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, Wensel R, Ripken F, Bremer H, Kluge S, Hoeffken G, Behr J. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691-694
34. Andreas S, Clemens C, Sandholzer H, Figulla HR, Kreuzer H. Improvement of exercise capacity with treatment of Cheyne-Stokes respiration in patients with congestive heart failure. J Am Coll Cardiol 1996;27:1486-1490
35. Giusca S, Jurcut R, Coman IM, Ghiorghiu I, Catrina D, Popescu BA, Dima L, Ginghina C. Right ventricular function predicts clinical response to specific vasodilator therapy in patients with pulmonary hypertension. Echocardiography 2012;30: 17-26
36. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, Ettinger NA, Hill NS, Summer WR, de Boisblanc B, Schwartz T, Koch G, Clayton LM, Jobsis MM, Crow JW, Long W. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39: 1214-1219
37. Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011;20:243-253
38. Morrison D, Caldwell J, Lakshminaryan S, Ritchie JL, Kennedy JW. The acute effects of lowflowoxygen and isosorbide dinitrate on left and right ventricular ejection fractions in chronic obstructive pulmonary disease. J Am Coll Cardiol 1983;2:652-660
39. Ikuma I, Ishibashi Y, Murakami Y, Nakazawa Y, Murakami R, Morioka S, Moriyama K. Improvement of right ventricular systolic performance by long-Term domiciliary oxygen therapy in patients with chronic respiratory failure. Jpn Circ J 1989;53: 756-765
40. Nussbaumer-Ochsner Y, Latshang TD, Ulrich S, Kohler M, Thurnheer R, Bloch KE. Patients with obstructive sleep apnea syndrome benefit from acetazolamide during an altitude sojourn: a randomized, placebo-controlled, double-blind trial. Chest 2012;141:131-138
41. DeBacker WA, Verbraecken J, Willemen M, Wittesaele W, DeCock W, Van deHeyning P. Central apnea index decreases after prolonged treatment with acetazolamide. Am J Respir Crit Care Med 1995;151:87-91
42. Fontana M, Emdin M, Giannoni A, Iudice G, Baruah R, Passino C. Effect of acetazolamide on chemosensitivity, Cheyne-Stokes respiration, and response to effort in patients with heart failure. Am J Cardiol 2011;107:1675-1680
43. Hohne C, Krebs MO, Seiferheld M, Boemke W, Kaczmarczyk G, Swenson ER. Acetazolamide prevents hypoxic pulmonary vasoconstriction in conscious dogs. J Appl Physiol 2004;97:515-521
44. Ritchie ND, Baggott AV, Andrew Todd WT. Acetazolamide for the prevention of acute mountain sickness-A systematic review and meta-Analysis. J Travel Med 2012;19:298-307
45. Lalande S, Snyder EM, Olson TP, Hulsebus ML, Orban M, Somers VK, Johnson BD, FrantzRP. The effects of sildenafil and acetazolamide onbreathing efficiency and ventilatory control during hypoxic exercise. Eur J Appl Physiol 2009;106:509-515
46. Gonzales JU, Scheuermann BW. Effect of acetazolamide on respiratory muscle fatigue in humans. Respir Physiol Neurobiol 2012;185:386-392